<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5864898</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.00510</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Human &#x003b3;&#x003b4; T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ravens</surname><given-names>Sarina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/515408"/></contrib><contrib contrib-type="author"><name><surname>Hengst</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/75594"/></contrib><contrib contrib-type="author"><name><surname>Schlapphoff</surname><given-names>Verena</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deterding</surname><given-names>Katja</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dhingra</surname><given-names>Akshay</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/522458"/></contrib><contrib contrib-type="author"><name><surname>Schultze-Florey</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koenecke</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/422088"/></contrib><contrib contrib-type="author"><name><surname>Cornberg</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/109243"/></contrib><contrib contrib-type="author"><name><surname>Wedemeyer</surname><given-names>Heiner</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02021;</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/353291"/></contrib><contrib contrib-type="author"><name><surname>Prinz</surname><given-names>Immo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02021;</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/24822"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Institute of Immunology, Hannover Medical School</institution>, <addr-line>Hannover</addr-line>, <country>Germany</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School</institution>, <addr-line>Hannover</addr-line>, <country>Germany</country></aff><aff id="aff3"><sup>3</sup><institution>Institute of Virology, Hannover Medical School</institution>, <addr-line>Hannover</addr-line>, <country>Germany</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School</institution>, <addr-line>Hannover</addr-line>, <country>Germany</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Gastroenterology and Hepatology, Essen University Hospital</institution>, <addr-line>Essen</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: David Vermijlen, Universit&#x000e9; Libre de Bruxelles, Belgium</p></fn><fn fn-type="edited-by"><p>Reviewed by: Robert Thimme, Albert Ludwigs Universit&#x000e4;t Freiburg, Germany; Tom Taghon, Ghent University, Belgium</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Sarina Ravens, <email>ravens.sarina@mh-hannover.de</email>; Immo Prinz, <email>prinz.immo@mh-hannover.de</email></corresp><fn fn-type="other" id="fn001"><p><sup>&#x02020;</sup>These authors have contributed equally to this work.</p></fn><fn fn-type="other" id="fn002"><p><sup>&#x02021;</sup>Shared senior authorship.</p></fn><fn fn-type="other" id="fn003"><p>Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>510</elocation-id><history><date date-type="received"><day>11</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Ravens, Hengst, Schlapphoff, Deterding, Dhingra, Schultze-Florey, Koenecke, Cornberg, Wedemeyer and Prinz.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Ravens, Hengst, Schlapphoff, Deterding, Dhingra, Schultze-Florey, Koenecke, Cornberg, Wedemeyer and Prinz</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Human &#x003b3;&#x003b4; T cells can contribute to clearance of hepatitis C virus (HCV) infection but also mediate liver inflammation. This study aimed to understand the clonal distribution of &#x003b3;&#x003b4; T cells in peripheral blood of chronic HCV patients and following HCV clearance by interferon-free direct-acting antiviral drug therapies. To this end, &#x003b3;&#x003b4; T cell receptor (TCR) repertoires were monitored by mRNA-based next-generation sequencing. While the percentage of V&#x003b3;9<sup>+</sup> T cells was higher in patients with elevated liver enzymes and a few expanded V&#x003b4;3 clones could be identified in peripheral blood of 23 HCV-infected non-cirrhotic patients, overall clonality and complexity of &#x003b3;&#x003b4; TCR repertoires were largely comparable to those of matched healthy donors. Monitoring eight chronic HCV patients before, during and up to 1&#x02009;year after therapy revealed that direct-acting antiviral (DAA) drug therapies induced only minor alterations of TRG and TRD repertoires of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cells. Together, we show that peripheral &#x003b3;&#x003b4; TCR repertoires display a high stability (1) by chronic HCV infection in the absence of liver cirrhosis and (2) by HCV clearance in the course of DAA drug therapy.</p></abstract><kwd-group><kwd>&#x003b3;&#x003b4; T cells</kwd><kwd>chronic hepatitis C virus</kwd><kwd>TRG</kwd><kwd>TRD</kwd><kwd>next-generation sequencing</kwd><kwd>direct-acting antivirals</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source><award-id rid="cn01">CRC900, IRGT1273</award-id></award-group><award-group><funding-source id="cn02">Deutsches Zentrum f&#x000fc;r Infektionsforschung<named-content content-type="fundref-id">10.13039/100009139</named-content></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="58"/><page-count count="9"/><word-count count="7594"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>The majority of hepatitis C virus (HCV) infection results in chronicity and only 10&#x02013;50% of cases are cleared in the acute phase (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Failing cytotoxic T cell activity due to exhaustion of expanded T cells causes chronic viral persistence and continuous activation of liver-infiltrating lymphocytes progressively leading to liver cirrhosis and development of hepatocellular carcinoma (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). However, the contribution of &#x003b3;&#x003b4; T cells to HCV control is largely unknown.</p><p>&#x003b3;&#x003b4; T cells are innate immune cells expressing a T cell receptor (TCR) consisting of a &#x003b3;- and a &#x003b4;-chain, each composed of a variable (V), diversity (D), and joining (J) gene segment generated by &#x0201c;VDJ recombination.&#x0201d; The random rearrangement of different gene segments creates a high clonal diversity, which is particularly reflected in the junctional regions (CDR3 sequence) of TCR chains. &#x003b3;&#x003b4; T cells can be classified based on their expressed V&#x003b3; or V&#x003b4; chains functionality and distribution within the body. The V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> subset is the main population of &#x003b3;&#x003b4; T cells within the peripheral blood of most adult healthy individuals (<xref rid="B6" ref-type="bibr">6</xref>). V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> cells are activated through small phosphoantigens, like microbial-derived HMB-PP or host-derived isopentyl pyrophosphate (IPP) (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>) and are involved in anti-cancer surveillance, pathogen clearance, or inflammatory diseases (<xref rid="B9" ref-type="bibr">9</xref>). By contrast, the identity of molecules activating non-V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> cells is largely unknown. Nevertheless, a few studies revealed that these could be stress molecules exposed by virus-infected or tumor cells (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>). Overall, non-V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> &#x003b3;&#x003b4; T cells exert a high degree of antiviral and antitumor activity (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>), which is for instance reflected in the expansion of V&#x003b4;1<sup>+</sup> &#x003b3;&#x003b4; T cells in response to viral infection in immunocompromised patients, stem cell transplant recipients, and during pregnancy (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>).</p><p>The functional role of different &#x003b3;&#x003b4; T cell populations in HCV persistence and associated liver malignancies remains to be understood. <italic>Per se</italic>, &#x003b3;&#x003b4; T cells are enriched not only in liver tissues of healthy persons but also in patients with hepatitis infections (<xref rid="B22" ref-type="bibr">22</xref>). Hepatic &#x003b3;&#x003b4; T cell populations express the NK-cell marker CD56, the liver-homing marker CD161, produce INF-&#x003b3;, and demonstrate an effector/memory phenotype (<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>). Especially, chronic HCV patients with liver cirrhosis display elevated &#x003b3;&#x003b4; T cell numbers and their cytokine production and cytotoxicity was suggested to play a role in inflammatory necrotic processes (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>). Studies analyzing matched blood and liver specimens from patients with chronic liver diseases indicated that V&#x003b4;2<sup>+</sup> and/or V&#x003b4;1<sup>+</sup> can infiltrate the liver (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Increased V&#x003b4;1<sup>+</sup> cell frequencies in liver transplant recipient were associated with high viral loads (HCV, CMV) (<xref rid="B30" ref-type="bibr">30</xref>). Likewise, patients infected with only HCV, or co-infected with HIV undergoing active antiretroviral therapy (HAART), had elevated V&#x003b4;1<sup>+</sup> &#x003b3;&#x003b4; T cells in the blood and liver, which was linked to liver inflammation (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Of note, HAART therapy did not restore intrahepatic V&#x003b4;1<sup>+</sup> T cells to normal levels within HCV/HIV co-infected patients (<xref rid="B31" ref-type="bibr">31</xref>). Especially, V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> cells have been revealed to inhibit viral replication (<xref rid="B32" ref-type="bibr">32</xref>). Other studies connect HCV persistence to low V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> frequencies, impaired IFN-&#x003b3; production, and &#x003b3;&#x003b4; T cell exhaustion (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>), while the cytotoxicity and continuous activation of V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> during chronic HCV infection contributes to liver inflammation and cirrhosis (<xref rid="B24" ref-type="bibr">24</xref>). The therapeutic application of zoledronate to activate V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> &#x003b3;&#x003b4; T cells through cellular accumulation of IPP was suggested as a strategy to apply &#x003b3;&#x003b4; T cells to inhibit viral replication during interferon-based therapies (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>).</p><p>Over the past few years, conventional HCV therapy based on PEG-INF&#x003b1;/ribavirin has been replaced by direct-acting antiviral (DAA) drugs. These DAA therapies result in increased cure rates defined by virus clearance and improve liver inflammation and cirrhosis in HCV-infected patients (<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>). Effects of DAAs and HCV clearance on the restoration of different immune cell subsets including HCV-specific T cells, NK cells, and MAIT cells have been analyzed in patients (<xref rid="B39" ref-type="bibr">39</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>). However, to the best of our knowledge, no study addressed the effect of DAA on &#x003b3;&#x003b4; T cell composition.</p><p>Next-generation sequencing (NGS) of TCR repertoires has the advantage to monitor &#x003b3;&#x003b4; T cell populations at the clonal level and to identify disease-related TRG (&#x003b3;-chain) and TRD (&#x003b4;-chain) sequences (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B44" ref-type="bibr">44</xref>). To understand the clonal distribution of &#x003b3;&#x003b4; T cells in patients with chronic HCV and to investigate in the influence of DAA on &#x003b3;&#x003b4; T cell repertoires, we used flow cytometric cell sorting and NGS to profile &#x003b3;&#x003b4; TCRs from total as well as V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> isolated &#x003b3;&#x003b4; T cell populations from peripheral blood.</p></sec><sec id="S2"><title>Results</title><sec id="S2-1"><title>Healthy and Chronic HCV Patients Show Similar &#x003b3;&#x003b4; T Cell Repertoire Complexity</title><p>We monitored peripheral &#x003b3;&#x003b4; T cell repertoires in 10 patients with chronic HCV infections before, during, and after therapy with DAAs and in additional 13 patients at a single time point during therapeutic DAA treatments. All patients had persistent viral infection with the HCV genotype 1 (Table <xref ref-type="table" rid="T1">1</xref> for patients&#x02019; characteristics). Even though parameters for liver inflammation, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level, were above normal levels in 4 of 10 patients (Table <xref ref-type="table" rid="T1">1</xref>), it is important to note that all patients included in this study had not yet developed liver cirrhosis. After flow cytometric sorting of &#x003b3;&#x003b4; T cells, the highly diverse CDR3 regions of the TCR &#x003b3;- and &#x003b4;-chain were PCR amplified through gene-specific primers and subjected to NGS analysis (<xref rid="B19" ref-type="bibr">19</xref>). The workflow to analyze multiple samples from 14 healthy controls (HC) and 23 chronic HCV patients is depicted in Figure S1A in Supplementary Material. Flow cytometric analyses showed slightly decreased total &#x003b3;&#x003b4; T cell frequencies, but a higher percentage of V&#x003b3;9<sup>+</sup> T cells, in patients with higher ALT levels when compared with HC and chronic HCV patients having low ALT levels (Figures <xref ref-type="fig" rid="F1">1</xref>A,B). NGS of functional V&#x003b3; or V&#x003b4; chain usage of TCR repertoires (Figures <xref ref-type="fig" rid="F1">1</xref>C,D) further indicated almost no difference of V-chain distributions between HC and chronic HCV patients. Of note, box plots in Figure <xref ref-type="fig" rid="F1">1</xref>D suggest that at least some of the chronic HCV-infected patients had higher peripheral V&#x003b4;3<sup>+</sup> frequencies and this was independent of ALT levels. To characterize &#x003b3;&#x003b4; T cell repertoires in more detail, we analyzed the clonal distribution and diversity of TRG and TRD repertoires (Figures <xref ref-type="fig" rid="F1">1</xref>E,F). As observed in previous datasets of HC (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>) and as illustrated by three HC of this study and six representative chronic HCV patients with different ALT levels, the 20 most expanded clones collectively made up between 25 and 60% of whole TRG or TRD repertoires (Figures <xref ref-type="fig" rid="F1">1</xref>E,F). Thus, &#x003b3;&#x003b4; TCR repertoires of chronic HCV patients largely resembled HC and were highly diverse with few expanded clones, that are not necessarily V&#x003b3;9JP<sup>+</sup> and V&#x003b4;2<sup>+</sup> (Figures <xref ref-type="fig" rid="F1">1</xref>E,F). All datasets were summarized by depicting the median frequency of top 20 clones and median Shannon index, a parameter used to measure TCR repertoire diversity, and showed no significant differences between the given groups (Figures S2A,B in Supplementary Material). Together, these NGS results indicate that peripheral TRG and TRD repertoires of healthy persons and chronic HCV patients have a similar complexity and clonal composition.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of healthy individuals and both cohorts of chronic HCV patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Healthy</th><th align="center" valign="top" rowspan="1" colspan="1">Chronic HCV (longitudinal samples)</th><th align="center" valign="top" rowspan="1" colspan="1">Chronic HCV (one time-point)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> (m/f)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (4/5), 5 (3/2)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (5/5)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (8/6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (26&#x02013;51), 44 (21&#x02013;66)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (47&#x02013;60)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (25&#x02013;79)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCV RNA (IU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2,913,000 (140,000&#x02013;6,700,000)</td><td align="center" valign="top" rowspan="1" colspan="1">1,893,000 (76,000&#x02013;6,300,000)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCV genotype</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">96.2 (51&#x02013;289)</td><td align="center" valign="top" rowspan="1" colspan="1">65.4 (22&#x02013;138)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">54.6 (24&#x02013;108)</td><td align="center" valign="top" rowspan="1" colspan="1">52.3 (24&#x02013;108)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gGT (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">55.9 (21&#x02013;107)</td><td align="center" valign="top" rowspan="1" colspan="1">108.6 (14&#x02013;558)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibroscan (kPa)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.4 (5.4&#x02013;12.3)</td><td align="center" valign="top" rowspan="1" colspan="1">7.9 (2.2&#x02013;24.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abs. lymphocyte count</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2,150 (1,600&#x02013;3,300)</td><td align="center" valign="top" rowspan="1" colspan="1">2,121 (1,200&#x02013;3,200)</td></tr></tbody></table><table-wrap-foot><p><italic>ALT, alanine aminotransferase; AST, aspartate aminotransferase; gGT, gamma-glutamyl transpeptidase; HCV, hepatitis C virus</italic>.</p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Comparison of peripheral &#x003b3;&#x003b4; T cell repertoires in chronic hepatitis C virus (HCV) patients and healthy controls (HC). <bold>(A,B)</bold> Flow cytometric sorting results of 9 HC (black dots) and 10 chronic HCV patients at baseline (blue dots), which were grouped based on their alanine aminotransferase (ALT) values, are summarized in dot plots representing <bold>(A)</bold> total &#x003b3;&#x003b4; T cell frequencies of CD14<sup>&#x02212;</sup>/CD19<sup>&#x02212;</sup> lymphocytes and <bold>(B)</bold> V&#x003b3;9<sup>+</sup> cell frequencies of total &#x003b3;&#x003b4; T cells. Six patients had ALT levels two times lower than upper limit of normal (&#x0003c;2&#x000d7; ULON) and four patients had increased ALT levels (&#x0003e;2&#x000d7; ULON). Horizontal lines present median values. Data were analyzed by Mann&#x02013;Whitney test. <bold>(C,D)</bold> Sorted &#x003b3;&#x003b4; T cells of eight HC and eight chronic HCV patients, the latter grouped based on their ALT levels, were subjected to next-generation sequencing (NGS) analysis. Floating bars from minimum to maximum represent the distribution of functional V-genes of analyzed <bold>(C)</bold> TRG or <bold>(D)</bold> TRD repertoires. Lines represent median values. <bold>(E,F)</bold> The most expanded top 20 <bold>(E)</bold> TRG or <bold>(F)</bold> TRD clones are highlighted in stacked area graphs of three representative HC and six HCV patients who were stratified due to their ALT levels. V&#x003b3;9<sup>&#x02212;</sup> or V&#x003b4;1<sup>+</sup> clones are highlighted in orange, V&#x003b3;9<sup>+</sup> or V&#x003b4;2<sup>+</sup> in gray, V&#x003b4;3<sup>+</sup> clones in green color, and non-top 20 clones in light gray. NGS samples were normalized to the percentage of all productive sequences per sample.</p></caption><graphic xlink:href="fimmu-09-00510-g001"/></fig></sec><sec id="S2-2"><title>DAA Drugs Lead to Minor Changes on &#x003b3;&#x003b4; T Cell Numbers</title><p>Next, we investigated the effect of DAA-induced viral clearance on peripheral &#x003b3;&#x003b4; T cell lymphocytes. Patients were treated for 8&#x02009;weeks with a combination of sofosbuvir and ledipasvir. All patients achieved a sustained virological response (Figure S1A in Supplementary Material). Six of ten patients were virus-negative at therapy week 4 (w4); HCV RNA levels of the other four patients were already very low at this time point (&#x0003c;20&#x02009;IU/mL) (Figure <xref ref-type="fig" rid="F2">2</xref>A). Some patients had mild liver fibrosis indicated by fibroscan values ranging from 5.4 to 12.3&#x02009;kPa, which decreased significantly from therapy start (TS) to follow-up week 12 (fu12) (Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>B). Some parameters for liver inflammation, such as ALT and AST levels, were slightly increased at TS (Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>C), while bilirubin values were ranging in the normal level below 17&#x02009;&#x000b5;mol/L (3.0&#x02013;14.0&#x02009;&#x000b5;mol/L) (Table <xref ref-type="table" rid="T1">1</xref>). During DAA therapy, ALT levels decreased significantly within the first therapy week and reached normal levels at week 4 (Figure <xref ref-type="fig" rid="F2">2</xref>C). After initiation of DAA therapy, a slight increase of absolute lymphocyte numbers and &#x003b3;&#x003b4; T cells/&#x003bc;L blood was observed (Figures <xref ref-type="fig" rid="F2">2</xref>D,E), which declined then until follow-up week 12 (Figure <xref ref-type="fig" rid="F2">2</xref>D). Furthermore, small changes in the number of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells/&#x003bc;L blood were detected during the first therapy weeks while staying stable during the follow-up year (Figures <xref ref-type="fig" rid="F2">2</xref>F,G). Of note, patients with ALT values higher than twofold ULON had very low numbers of V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells/&#x003bc;L blood (Figure <xref ref-type="fig" rid="F2">2</xref>G), whereas the number of V&#x003b3;9<sup>+</sup> &#x003b3;&#x003b4; T cells/&#x003bc;L blood and their progression was similar to patients with ALT values lower than twofold ULON (Figure <xref ref-type="fig" rid="F2">2</xref>F). Altogether, patients improved with regard to liver inflammation and stiffness following successful eradication of HCV infection, while total numbers of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells remained highly stable after viral clearance. This suggests that potential alterations in &#x003b3;&#x003b4; T cell numbers and repertoire composition in response to HCV infection were sustained for the observation period of 48&#x02009;weeks.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Clinical parameters and &#x003b3;&#x003b4; T cell numbers in chronic hepatitis C virus (HCV) patients receiving DAA therapy. Graphs represent <bold>(A)</bold> HCV RNA levels in IU/mL and <bold>(B)</bold> alanine aminotransferase (ALT) levels in IU/mL, statistical analysis for both parameters with Wilcoxon test, as well as <bold>(C)</bold> fibroscan values in kPa, statistical analysis with paired <italic>t</italic>-test. <bold>(A&#x02013;C)</bold> Median values with interquartile range from 10 chronic HCV patients before, during, and after DAA therapy are summarized. <bold>(D)</bold> Absolute lymphocyte counts were assessed for 10 chronic HCV patients at given time points. <bold>(E&#x02013;G)</bold> The number of total <bold>(E)</bold>, V&#x003b3;9<sup>+</sup>
<bold>(F)</bold>, or V&#x003b3;9<sup>&#x02212;</sup>
<bold>(G)</bold> &#x003b3;&#x003b4; T cells per &#x003bc;L blood were determined from FACS data and lymphocyte counts shown for each of the 10 HCV patients individually. Gray shaded areas highlight the 8&#x02009;weeks of DAA treatment. The number of total <bold>(E)</bold>, V&#x003b3;9<sup>+</sup>
<bold>(F)</bold>, or V&#x003b3;9<sup>&#x02212;</sup>
<bold>(G)</bold> &#x003b3;&#x003b4; T cells per &#x003bc;L blood were separated based on the ALT levels (red shows patients who have ALT levels &#x0003e;2 times ULON, blue indicates patients who have ALT levels &#x0003c;2 times ULON). Gray shaded areas highlight the 8-week DAA treatment.</p></caption><graphic xlink:href="fimmu-09-00510-g002"/></fig></sec><sec id="S2-3"><title>TRD Repertoires of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T Cells Are Distinct</title><p>Next, we investigated V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cells separately. Flow cytometric profiling of &#x003b3;&#x003b4; T cells specified a fraction of V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;2<sup>+</sup> cells in the peripheral blood of adults and chronic HCV patients (Figure <xref ref-type="fig" rid="F3">3</xref>A), which is in line with the identification of expanded V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;2<sup>+</sup> clones in HC and transplant recipients (<xref rid="B19" ref-type="bibr">19</xref>). In adults, TRD repertoires are highly individual, while all TRG repertoires comprise public V&#x003b3;9JP rearrangements shared between all persons (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Here, we analyzed TRD repertoires of sorted V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells from 11 HC and 20 chronic HCV patients receiving DAA therapy (Table <xref ref-type="table" rid="T1">1</xref>; Figure S1 in Supplementary Material). First, we studied the distribution of &#x003b4;-chains within the V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> subsets in HC and chronic HCV patients. As depicted by boxplots (Figures <xref ref-type="fig" rid="F3">3</xref>B,C), V&#x003b3;9<sup>+</sup> cells paired mainly with V&#x003b4;2<sup>+</sup> sequences, while V&#x003b3;9<sup>&#x02212;</sup> cells paired with V&#x003b4;1, V&#x003b4;2, and V&#x003b4;3 sequences. In addition, the proportion of V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> cells was on average slightly increased in chronic HCV patients when compared with HC (Figures <xref ref-type="fig" rid="F1">1</xref>D and <xref ref-type="fig" rid="F3">3</xref>C) and could be associated with the identification of some expanded V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> clones (Figure <xref ref-type="fig" rid="F3">3</xref>D). Next, we analyzed the clonal distribution of the 20 most expanded TRD clones of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> sorted cells from three representative HC (Figure <xref ref-type="fig" rid="F3">3</xref>E) and three chronic HCV patients (Figure <xref ref-type="fig" rid="F3">3</xref>F). Similar to total &#x003b3;&#x003b4; T cell populations, TRD repertoires of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cell subsets were diverse and depicted an oligoclonal expansion of particular V&#x003b3;9<sup>+</sup>V&#x003b4;2<sup>+</sup>, V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;2<sup>&#x02212;</sup>, and V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;2<sup>+</sup> clones (Figures <xref ref-type="fig" rid="F3">3</xref>E,F). Comparison of the combined median frequency of the top 20 V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> TRD clones between HC and chronic HCV patients pointed to lower frequencies of top 20 clones in V&#x003b3;9<sup>+</sup> cells of the HC group (Figure <xref ref-type="fig" rid="F3">3</xref>G). However, individual TRD repertoires were very diverse in the analyzed groups and thus differences in top 20 frequencies (Figure <xref ref-type="fig" rid="F3">3</xref>G) and TRD repertoire diversities as measured by Shannon indices (Figure <xref ref-type="fig" rid="F3">3</xref>H) were not statistically significant. Still, separate analyses of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> sorted &#x003b3;&#x003b4; T cells revealed that V&#x003b3;9<sup>&#x02212;</sup> TRD repertoires displayed a high V&#x003b4;-chain diversity and that expanded V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> clones existed in some chronic HCV patients, while the overall clonal composition of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> TRD repertoires was comparable between healthy persons and chronic HCV patients. Further studies, preferably also including patients with more severe HCV disease, will be required to support or refute the hypothesis that V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> clones selectively expand in response to HCV infection.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Differences between TRD repertoires of sorted V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cells in healthy controls (HC) and chronic hepatitis C virus (HCV) patients. <bold>(A)</bold> Flow cytometric analysis of total &#x003b3;&#x003b4; T cells for expression of V&#x003b3;9 and V&#x003b4;2 in six HC and three chronic HCV patients. <bold>(B&#x02013;H)</bold> TRD next-generation sequencing analysis of sorted V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells from 11 HC and 23 HCV patients. <bold>(B,C)</bold> Fractions of V-delta chains within the sorted <bold>(B)</bold> V&#x003b3;9<sup>+</sup> and <bold>(C)</bold> V&#x003b3;9<sup>&#x02212;</sup> populations of HC and HCV patients are represented as floating bars from minimum to maximum with the line representing the median. <bold>(D)</bold> Identified V&#x003b4;3<sup>+</sup> sequences within sorted V&#x003b3;9<sup>&#x02212;</sup> cells of chronic HCV patients. <bold>(E,F)</bold> Top 20 expanded TRD clones of either V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> cells are plotted in stacked area graphs for <bold>(E)</bold> three HC or <bold>(F)</bold> three HCV patients. V&#x003b4;2<sup>+</sup> are depicted in gray, V&#x003b4;1<sup>+</sup> clones in orange, and V&#x003b4;3<sup>+</sup> clones in green. Light gray represents non-top 20 TRD clones. Data sets were normalized to the percentage of productive reads per sample. <bold>(G)</bold> Dot plot displays the proportion of top 20 TRD clones within the V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cell compartments for each analyzed sample. <bold>(H)</bold> TRD repertoire diversity of either V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> analyzed samples were determined by Shannon diversity indices. Samples were normalized to 10,000 productive reads. Median values are depicted as horizontal lines. Statistical analysis was performed using one-way ANOVA.</p></caption><graphic xlink:href="fimmu-09-00510-g003"/></fig></sec><sec id="S2-4"><title>Stability of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> TRD Repertoires During DAA Drug Therapy</title><p>Finally, we asked whether chronic HCV infection and DAA-driven viral clearance would affect &#x003b3;&#x003b4; T cell repertoires, which otherwise stay relatively stable over time (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>). For this, we analyzed &#x003b3;&#x003b4; TCR repertoires at TS, during DAA treatment and up to 1&#x02009;year after therapy (illustrated in Figure S1A in Supplementary Material). We studied the TRD repertoires of sorted V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> cells as well as TRG and TRD repertoires of total &#x003b3;&#x003b4; T cells. First, no significant changes in median frequencies of the top 20 clones and Shannon diversity indices of the analyzed cell subsets reflected that &#x003b3;&#x003b4; TCR repertoires retained the overall complexity during the course of DAA drug therapy (Figures <xref ref-type="fig" rid="F4">4</xref>A,B; Figures S3A,B in Supplementary Material). Plotting the most expanded 20 TRD clones of either V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> sorted cells (Figure <xref ref-type="fig" rid="F4">4</xref>C) and the top 20 TRG and TRD clones of total &#x003b3;&#x003b4; T cells (Figure S3C in Supplementary Material) over time, it turned out that only one patient (patient 3) showed notable changes in the distribution of expanded clones after TS. Importantly, this instability was caused by changes in V&#x003b4;2<sup>+</sup> sequences of V&#x003b3;9<sup>+</sup> sorted cells (Figure <xref ref-type="fig" rid="F4">4</xref>C). These might have been associated with increased &#x003b3;&#x003b4; T cell counts starting from w1, but no other clinical parameters. Furthermore, &#x003b3;&#x003b4;TCR repertoire stability can be described in similarities between two given time points as calculated by Morisita&#x02013;Horn indices. Notably, the Morisita&#x02013;Horn index considers all clones of the given repertoire, while zero means no overlap and one represents complete overlap between all clones of given samples. Median values of calculated Morisita&#x02013;Horn similarity indices revealed only minor changes of &#x003b3;&#x003b4; T cell repertoires before, during, and after DAA drug therapy (Figure <xref ref-type="fig" rid="F4">4</xref>D; Figure S3D in Supplementary Material). In summary, &#x003b3;&#x003b4; TCR repertoires of total, V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells retained their overall complexity during DAA therapy and were highly stable up to 1&#x02009;year after viral clearance and normalization of liver enzymes.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Monitoring of TRD repertoires of V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells in hepatitis C virus (HCV) patients over time. Next-generation sequencing results of TRD repertoires from sorted V&#x003b3;9<sup>+</sup> or V&#x003b3;9<sup>&#x02212;</sup> cells of six chronic HCV patients receiving DAA therapy overtime (TS: therapy start; therapy week 1 and week 4: w1, w4; follow-up weeks: fu12, fu48). <bold>(A)</bold> TRD repertoire diversities were determined by Shannon values for V&#x003b3;9<sup>+</sup> (left side) and V&#x003b3;9<sup>&#x02212;</sup> (right side) cells. Samples were normalized to 10,000 productive reads. <bold>(B)</bold> Frequency of top 20 TRD clones of sorted V&#x003b3;9<sup>+</sup> (left side) and V&#x003b3;9<sup>&#x02212;</sup> (right side) cells. <bold>(C)</bold> Stacked area graphs illustrate the distribution of top 20 TRD clones within sorted V&#x003b3;9<sup>+</sup> (left side) or V&#x003b3;9<sup>&#x02212;</sup> (right side) cells of chronic HCV patients from TS up to 1&#x02009;year after DAA treatment (fu48). V&#x003b4;2<sup>+</sup> clones are highlighted in gray, V&#x003b4;1<sup>+</sup> clones in orange, and V&#x003b4;3<sup>+</sup> clones in green. Light gray stands for non-top 20 TRD clones. Data sets were normalized to the percentage of productive reads. Horizontal lines represent median values. <bold>(D)</bold> To compare the TRD repertoire similarity between the given time points of either V&#x003b3;9<sup>+</sup> (left side) or V&#x003b3;9<sup>&#x02212;</sup> (right side) cells, Morisita&#x02013;Horn indices were calculated and visualized as dot plots. Zero means no overlap and one total overlap between all CDR3 sequences of two samples.</p></caption><graphic xlink:href="fimmu-09-00510-g004"/></fig></sec></sec><sec sec-type="materials|methods" id="S3"><title>Materials and Methods</title><sec id="S3-1"><title>Patient Characteristics</title><p>All 23 patients chronically infected with HCV as well as 9 HC were recruited at the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany. In addition, five HC were recruited at the Institute of Immunology/Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, Germany. The chronic HCV patients were analyzed over time before, during, and after novel DAA therapy for 8&#x02009;weeks with a combination of sofosbuvir and ledipasvir. From 10 patients, peripheral blood mononuclear cells were collected at treatment start (TS), therapy week 1 (w1), therapy week 4 (w4), follow-up week 12 (fu12), and 1&#x02009;year after treatment cessation (fu48), isolated and cryopreserved for deferred analysis. Further, 13 chronic HCV patients who were treated for 8 or 12&#x02009;weeks with a combination of sofosbuvir and ledipasvir were included in the study with only one time-point during or after treatment to determine their TRD repertoires.</p><p>The ethics committee of Hannover Medical School approved this study (Study number: 2148-2014 and 2604-2014), and all patients provided written confirmed consent before enrollment. The clinical characteristics of the chronic HCV patients and the HC are summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p></sec><sec id="S3-2"><title>Flow Cytometric Analysis and Sorting</title><p>PBMCs were thawed, washed twice, and stained for 20&#x02009;min at room temperature for flow cytometric analysis and cell sorting with the following antibodies: LIVE/DEAD Fixable Green Dead cell Stain Kit, Thermofisher or DAPI; CD14-FITC, clone M5E2, BD Biosciences; CD19-FITC, clone HIB19, BD Biosciences; &#x003b3;&#x003b4; TCR-PE, clone 11F2, eBiosciences; V&#x003b3;9-PE-Cy5, clone IMMU 360, Beckman Coulter; V&#x003b4;2-APC, clone 123R4, Miltenyi; CD45-APC-Cy7, clone 5B1, Miltenyi; CD3-BV786 and CD3-PECy7, clone UCHT1, BD Biosciences. After staining, PBMCs were washed twice and stored on ice until acquisition and sorting on a FACSAria Fusion cell sorter (BD Biosciences). HC and patients recruited at the Department of Gastroenterology, Hepatology and Endocrinology were sorted for CD14<sup>&#x02212;</sup>/CD19<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells and HC recruited at the Institute for Immunology were sorted for CD45<sup>+</sup>/CD3<sup>+</sup> &#x003b3;&#x003b4; T cells. Flow cytometry data were analyzed using the Flow Jo software V.9.8 (Tree Star Inc., Ashland, OR, USA).</p></sec><sec id="S3-3"><title>TCR Amplicon Generation and NGS</title><p>For cDNA synthesis, extracted mRNA using the RNAeasy mini kit (Qiagen) of flow cytometric sorted V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cells, 5&#x02009;&#x000b5;L mRNA of both subsets was pooled equally for analysis of total &#x003b3;&#x003b4; T cells. CDR3 TRG and TRD sequencing amplicons were generated as described previously (<xref rid="B19" ref-type="bibr">19</xref>), while using 25&#x02013;30 PCR cycles. According to Illumina guidelines 96 samples were labeled with Nextera XT indices and subjected to Illumina MiSeq analysis using 500 cycle paired-end sequencing. 20% PhIX was added as an internal control and to increase library complexity. Illumina output fastq files were processed using ea-utils.</p></sec><sec id="S3-4"><title>TCR Repertoire Analysis</title><p>All sequencing files were annotated according to IMGT/High-Vquest. Only productive reads were taken into consideration for downstream processing of annotated sequences. Repertoire analyses were based on CDR3 amino acid sequences. Annotated V-chains were counted and CDR3 sequences were ranked according to their abundance to finally normalize the results to the percentage of productive reads within the given sample. All bioinformatics analysis was conducted using R (version 3.2.2) and bash shell commands. Shannon indices were calculated with the R library &#x0201c;vegan&#x0201d; and Morisita&#x02013;Horn indices with VDJtools (<xref rid="B47" ref-type="bibr">47</xref>) and TcR (<xref rid="B48" ref-type="bibr">48</xref>). Analysis scripts are available upon request.</p></sec><sec id="S3-5"><title>Statistical Analysis</title><p>Data were analyzed using the GraphPad Prism version 6.0b and 4.0. To test for normal distribution of data, D&#x02019;Agostino and Pearson omnibus normality test was applied. Normally distributed data of multiple or two groups was analyzed using the one-way ANOVA, paired <italic>t</italic>-test, or unpaired <italic>t</italic>-test depending on the data sets that were compared. Regarding non-normally distributed data, the Mann&#x02013;Whitney test or Wilcoxon matched-pairs signed rank test was used.</p></sec><sec id="S3-6"><title>Data Availability</title><p>SRA files have been deposited at SRP128752.</p></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>In this study, we monitored peripheral &#x003b3;&#x003b4; T cell repertoire dynamics in a homogenous cohort of chronic HCV patients before and during DAA therapy. All HCV patients had similar characteristics by being persistently infected with the HCV genotype 1, by no development of liver cirrhosis and by receiving a short 8&#x02009;weeks therapeutic drug treatment. It was reasonable to expect an impact of chronic HCV infection and its clearance on &#x003b3;&#x003b4; T cell dynamics, because &#x003b3;&#x003b4; T cells play a role in the antiviral defense of CMV, HCV, and other viruses (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). During HCV infection, cytokine release (IFN-&#x003b3;) by V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> and non-V&#x003b3;9JP<sup>+</sup>V&#x003b4;2<sup>+</sup> may contribute to virus clearance, while HCV persistence is associated with low &#x003b3;&#x003b4; T cell numbers and an impaired cytokine production (<xref rid="B22" ref-type="bibr">22</xref>). By contrast, chronic HCV patients with high liver inflammation rather have increased frequencies of cytotoxic &#x003b3;&#x003b4; T cells when compared with healthy subjects or patients with no liver inflammation. In our study, all chronic HCV patients included had no or only mild liver fibrosis and mild liver inflammation, which might explain that they displayed no significantly, elevated numbers of &#x003b3;&#x003b4; T cells. Importantly, eradication of the viral infection resulted in significant improvement of liver stiffness and inflammation as revealed by fibroscan values and ALT levels. Overall, our TCR analyses showed that uncomplicated chronic HCV infection and rapid viral clearance had only minor effects on the peripheral &#x003b3;&#x003b4; T cell compartment, indicating that more drastic immunological events are required for perturbation of peripheral &#x003b3;&#x003b4; T cell repertoires (<xref rid="B19" ref-type="bibr">19</xref>). However, we cannot exclude that TCR repertoires in the liver might be more affected by HCV clearance. Also, patients with liver cirrhosis may show more pronounced alterations of TCR repertoires during DAA therapy.</p><p>This study characterized, in addition to the analysis of total &#x003b3;&#x003b4; T cell populations in peripheral blood, TRD repertoires of sorted V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cells separately. As already demonstrated in preterm-infants and neonates, V&#x003b4;2 sequences pair mainly, but not exclusively with V&#x003b3;9JP<sup>+</sup> TRG sequences (<xref rid="B51" ref-type="bibr">51</xref>). Flow cytometric results and TRD repertoire analysis of this study pointed out that V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;2<sup>+</sup> T cells are maintained until adulthood. While V&#x003b3;9<sup>+</sup> cells displayed a more homogenous V&#x003b4;-chain usage (mainly V&#x003b4;2), TRD repertoires of V&#x003b3;9<sup>&#x02212;</sup> cells were more diverse and consisted of V&#x003b4;1<sup>+</sup>, V&#x003b4;2<sup>+</sup>, V&#x003b4;3<sup>+</sup>, but very little V&#x003b4;5<sup>+</sup> sequences. Clonal distributions and the complete absence of any shared expanded TRD clones collectively illustrated that similar to all &#x003b3;&#x003b4; T cells (<xref rid="B19" ref-type="bibr">19</xref>), V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> TRD repertoires are generally oligoclonal and individual. Although &#x003b3;&#x003b4; TCR repertoires showed only minor alterations within patients with mild HCV infections, we identified several expanded V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> &#x003b3;&#x003b4; T cell clones present in the peripheral blood of some chronic HCV patients. In general, V&#x003b4;3<sup>+</sup> cells are highly enriched in the liver, but not in the blood, of healthy persons (<xref rid="B23" ref-type="bibr">23</xref>). Since in routine clinical practice liver biopsies are no longer performed in uncomplicated HCV infection and patient sampling starts only after diagnosis of persistent HCV infection, we can only speculate that these liver-specific V&#x003b4;3<sup>+</sup> cells might undergo a HCV-induced clonal expansion to finally circulate in the peripheral blood of chronic HCV patients. Presence of NK cell markers and liver-homing markers (e.g., CD161) could strengthen the hypothesis V&#x003b4;3<sup>+</sup> &#x003b3;&#x003b4; T cell clones can be associated with liver specificity. In addition, it should be worthwhile to investigate a potential HCV-related antigen specificity of expanded V&#x003b3;9<sup>&#x02212;</sup>V&#x003b4;3<sup>+</sup> &#x003b3;&#x003b4; T cell clones in future <italic>in vitro</italic> studies.</p><p>Another important finding of this study was the absence of significant and detectable effects of novel DAA therapy on &#x003b3;&#x003b4; T cell frequencies and their TCR repertoires in peripheral blood. This is remarkable as the systemic inflammatory milieu shows profound changes already early during antiviral therapy&#x02014;even though no complete restoration of various soluble inflammatory parameters occurs (<xref rid="B40" ref-type="bibr">40</xref>). The effect of spontaneous clearance of acute HCV infection and a longitudinal follow-up would be an appropriate control; however, those patients are rarely seen in the clinics. It is conceivable that &#x003b3;&#x003b4; T cells might contribute to successful resolution of the disease. Nevertheless, the finding that peripheral &#x003b3;&#x003b4; T cell compartments and their associated TCR repertoires were highly stable even 1&#x02009;year after viral elimination is in line with previous observations for other cell types. This may suggest that distinct imprints on the immune system by long-lasting HCV infection can persist for years despite eradication of HCV, which may have clinical implications for some hepatic and extrahepatic disease manifestations. For instance, no changes in the short-term risk to develop hepatocellular carcinoma upon DAA treated were observed in the analyzed cohort of HCV patients (<xref rid="B52" ref-type="bibr">52</xref>). With regard to NK cells, it has been suggested that phenotypic and functional alterations during chronic HCV infections could be restored upon DAA therapy (<xref rid="B53" ref-type="bibr">53</xref>). NK cell phenotypes were altered upon IFN-free DAA treatment further resulting in modifications of the transcription factor profiles (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). T cells have also been studied in HCV infection and during DAA-related viral eradication. The proliferative capacity of HCV-responsive CD8<sup>+</sup> T cells could be restored in part (<xref rid="B56" ref-type="bibr">56</xref>) and a decrease in PD-1 expression on CD8<sup>+</sup> T cells was observed upon successful DAA treatment (<xref rid="B55" ref-type="bibr">55</xref>). On the other hand, neither the frequency nor the phenotype of regulatory T cells was rescued upon viral clearance (<xref rid="B57" ref-type="bibr">57</xref>). Likewise, MAIT cells were reduced in frequency and their functions are affected by chronic HCV infection (<xref rid="B58" ref-type="bibr">58</xref>), and in particular peripheral MAIT cells could not be restored upon viral eradication (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). All these studies were analyzing the phenotypic and functional changes of given immune cells by flow cytometry. Our data now contribute that the frequency of peripheral &#x003b3;&#x003b4; T cell populations is neither affected by uncomplicated chronic HCV infection with no liver inflammation <italic>per se</italic> nor by rapid viral eradication upon DAA therapy. Likewise, conventional PEG-IFN&#x003b1;/Ribavirin therapy might not significantly change &#x003b3;&#x003b4; T cell numbers; however, the presence of IFN&#x003b1; during this treatment regime may stimulate cytokine production by V&#x003b3;9<sup>+</sup>V&#x003b4;2<sup>+</sup> (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). In this study, peripheral V&#x003b3;9<sup>+</sup> and V&#x003b3;9<sup>&#x02212;</sup> cell TCR repertoires were largely undisturbed with regard to oligoclonality and TCR diversity by rapid viral clearance using IFN-free DAA therapies. During and after DAA treatment, peripheral &#x003b3;&#x003b4; TCR repertoires displayed a high stability for up to 1&#x02009;year, indicating that there is no dominant acute anti-HCV response of &#x003b3;&#x003b4; T cells in patients with chronic HCV infection and also consistent with the assumption that chronic viral infection might leave a sustained footprint on the &#x003b3;&#x003b4; T cell compartment in peripheral blood.</p></sec><sec id="S5"><title>Ethics Statement</title><p>The ethics committee of Hannover Medical School approved this study (Study number: 2148-2014 and 2604-2014), and all patients provided written confirmed consent before enrollment.</p></sec><sec id="S6"><title>Author Contributions</title><p>SR, JH, and VS conducted, analyzed, and interpreted experiments. CS-F recruited and organized healthy controls. SR and AD performed NGS. KD collected and organized HCV patient samples. CK, MC, HW, and IP discussed data and designed the study. SR, JH, HW, and IP wrote the manuscript.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We would like to thank Matthias Ballmeier of the MHH cell sorting facility for flow cytometric sorting, Solaiman Raha for bioinformatics support, Melanie Drenker for isolation of peripheral blood lymphocytes of healthy control samples and the Genomics platform of the HZI Braunschweig as well as Z1-project of the Sonderforschungsbereich 900 for Illumina MiSeq sequencing.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The study was supported by Deutsche Forschungsgemeinschaft (CRC900 to IP), CK, MC, and HW and IRTG1273 to JH; by Hannover Medical School young investigator funds (MHH-HILF to SR); by DZIF to HW; and by HepNet study house for HW and MC. Deutsche Forschungsgemeinschaft DFG PR727/4-1 to IP, COALITION to SR and IP.</p></fn></fn-group><sec id="S8" sec-type="supplementary-material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at <uri xlink:type="simple" xlink:href="http://www.frontiersin.org/articles/10.3389/fimmu.2018.00510/full#supplementary-material">http://www.frontiersin.org/articles/10.3389/fimmu.2018.00510/full#supplementary-material</uri>.</p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Image_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Image_2.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Image_3.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Gruner</surname><given-names>N</given-names></name><name><surname>Buggisch</surname><given-names>P</given-names></name><name><surname>Wiegand</surname><given-names>J</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Spengler</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial</article-title>. <source>Lancet Infect Dis</source> (<year>2013</year>) <volume>13</volume>:<fpage>497</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="doi">10.1016/S1473-3099(13)70059-8</pub-id><?supplied-pmid 23523674?><pub-id pub-id-type="pmid">23523674</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santantonio</surname><given-names>T</given-names></name><name><surname>Wiegand</surname><given-names>J</given-names></name><name><surname>Gerlach</surname><given-names>JT</given-names></name></person-group>. <article-title>Acute hepatitis C: current status and remaining challenges</article-title>. <source>J Hepatol</source> (<year>2008</year>) <volume>49</volume>:<fpage>625</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.jhep.2008.07.005</pub-id><?supplied-pmid 18706735?><pub-id pub-id-type="pmid">18706735</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Thimme</surname><given-names>R</given-names></name></person-group>. <article-title>T cell responses in hepatitis C: the good, the bad and the unconventional</article-title>. <source>Gut</source> (<year>2012</year>) <volume>61</volume>:<fpage>1226</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1136/gutjnl-2011-300620</pub-id><?supplied-pmid 21873736?><pub-id pub-id-type="pmid">21873736</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehermann</surname><given-names>B</given-names></name></person-group>. <article-title>Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>:<fpage>859</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1038/nm.3251</pub-id><?supplied-pmid 23836236?><pub-id pub-id-type="pmid">23836236</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debes</surname><given-names>JD</given-names></name><name><surname>de Knegt</surname><given-names>RJ</given-names></name><name><surname>Boonstra</surname><given-names>A</given-names></name></person-group>. <article-title>The Path to cancer and back: immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals</article-title>. <source>Transplantation</source> (<year>2017</year>) <volume>101</volume>:<fpage>910</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1097/TP.0000000000001623</pub-id><?supplied-pmid 28045877?><pub-id pub-id-type="pmid">28045877</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermijlen</surname><given-names>D</given-names></name><name><surname>Prinz</surname><given-names>I</given-names></name></person-group>. <article-title>Ontogeny of innate T lymphocytes &#x02013; some innate lymphocytes are more innate than others</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<fpage>486</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2014.00486</pub-id><?supplied-pmid 25346734?><pub-id pub-id-type="pmid">25346734</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puan</surname><given-names>KJ</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sarikonda</surname><given-names>G</given-names></name><name><surname>Raker</surname><given-names>AM</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><etal/></person-group>
<article-title>Preferential recognition of a microbial metabolite by human Vgamma2Vdelta2 T cells</article-title>. <source>Int Immunol</source> (<year>2007</year>) <volume>19</volume>:<fpage>657</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxm031</pub-id><?supplied-pmid 17446209?><pub-id pub-id-type="pmid">17446209</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>CT</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nieves</surname><given-names>E</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name></person-group>. <article-title>Natural and synthetic non-peptide antigens recognized by human gamma delta T cells</article-title>. <source>Nature</source> (<year>1995</year>) <volume>375</volume>:<fpage>155</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/375155a0</pub-id><?supplied-pmid 7753173?><pub-id pub-id-type="pmid">7753173</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>W</given-names></name></person-group>
<article-title>The multifunctionality of human Vgamma9Vdelta2 gammadelta T cells: clonal plasticity or distinct subsets?</article-title>
<source>Scand J Immunol</source> (<year>2012</year>) <volume>76</volume>:<fpage>213</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02727.x</pub-id><pub-id pub-id-type="pmid">22670577</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marlin</surname><given-names>R</given-names></name><name><surname>Pappalardo</surname><given-names>A</given-names></name><name><surname>Kaminski</surname><given-names>H</given-names></name><name><surname>Willcox</surname><given-names>CR</given-names></name><name><surname>Pitard</surname><given-names>V</given-names></name><name><surname>Netzer</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Sensing of cell stress by human gammadelta TCR-dependent recognition of annexin A2</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2017</year>) <volume>114</volume>:<fpage>3163</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1621052114</pub-id><pub-id pub-id-type="pmid">28270598</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willcox</surname><given-names>CR</given-names></name><name><surname>Pitard</surname><given-names>V</given-names></name><name><surname>Netzer</surname><given-names>S</given-names></name><name><surname>Couzi</surname><given-names>L</given-names></name><name><surname>Salim</surname><given-names>M</given-names></name><name><surname>Silberzahn</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor</article-title>. <source>Nat Immunol</source> (<year>2012</year>) <volume>13</volume>:<fpage>872</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2394</pub-id><pub-id pub-id-type="pmid">22885985</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Castro</surname><given-names>CD</given-names></name><name><surname>Mayassi</surname><given-names>T</given-names></name><name><surname>Bembinster</surname><given-names>LA</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>39</volume>:<fpage>1032</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.001</pub-id><pub-id pub-id-type="pmid">24239091</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uldrich</surname><given-names>AP</given-names></name><name><surname>Le Nours</surname><given-names>J</given-names></name><name><surname>Pellicci</surname><given-names>DG</given-names></name><name><surname>Gherardin</surname><given-names>NA</given-names></name><name><surname>McPherson</surname><given-names>KG</given-names></name><name><surname>Lim</surname><given-names>RT</given-names></name><etal/></person-group>
<article-title>CD1d-lipid antigen recognition by the gammadelta TCR</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>:<fpage>1137</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2713</pub-id><pub-id pub-id-type="pmid">24076636</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Pizarro</surname><given-names>JC</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>McBeth</surname><given-names>C</given-names></name><name><surname>Groh</surname><given-names>V</given-names></name><name><surname>Spies</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2011</year>) <volume>108</volume>:<fpage>2414</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1015433108</pub-id><?supplied-pmid 21262824?><pub-id pub-id-type="pmid">21262824</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva-Santos</surname><given-names>B</given-names></name><name><surname>Serre</surname><given-names>K</given-names></name><name><surname>Norell</surname><given-names>H</given-names></name></person-group>
<article-title>&#x003b3;&#x003b4; T cells in cancer</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>15</volume>:<fpage>683</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/nri3904</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vantourout</surname><given-names>P</given-names></name><name><surname>Hayday</surname><given-names>A</given-names></name></person-group>
<article-title>Six-of-the-best: unique contributions of gammadelta T cells to immunology</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>13</volume>:<fpage>88</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="doi">10.1038/nri3384</pub-id><pub-id pub-id-type="pmid">23348415</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dechanet</surname><given-names>J</given-names></name><name><surname>Merville</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Retiere</surname><given-names>C</given-names></name><name><surname>Pitard</surname><given-names>V</given-names></name><name><surname>Lafarge</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Implication of gammadelta T cells in the human immune response to cytomegalovirus</article-title>. <source>J Clin Invest</source> (<year>1999</year>) <volume>103</volume>:<fpage>1437</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1172/JCI5409</pub-id><?supplied-pmid 10330426?><pub-id pub-id-type="pmid">10330426</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>A</given-names></name><name><surname>Madrigal</surname><given-names>AJ</given-names></name><name><surname>Grace</surname><given-names>S</given-names></name><name><surname>Sivakumaran</surname><given-names>J</given-names></name><name><surname>Kottaridis</surname><given-names>P</given-names></name><name><surname>Mackinnon</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>:<fpage>2164</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-01-255166</pub-id><pub-id pub-id-type="pmid">20576814</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravens</surname><given-names>S</given-names></name><name><surname>Schultze-Florey</surname><given-names>C</given-names></name><name><surname>Raha</surname><given-names>S</given-names></name><name><surname>Sandrock</surname><given-names>I</given-names></name><name><surname>Drenker</surname><given-names>M</given-names></name><name><surname>Oberdorfer</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>:<fpage>393</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3686</pub-id><pub-id pub-id-type="pmid">28218745</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitard</surname><given-names>V</given-names></name><name><surname>Roumanes</surname><given-names>D</given-names></name><name><surname>Lafarge</surname><given-names>X</given-names></name><name><surname>Couzi</surname><given-names>L</given-names></name><name><surname>Garrigue</surname><given-names>I</given-names></name><name><surname>Lafon</surname><given-names>ME</given-names></name><etal/></person-group>
<article-title>Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>:<fpage>1317</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2008-01-136713</pub-id><?supplied-pmid 18539896?><pub-id pub-id-type="pmid">18539896</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermijlen</surname><given-names>D</given-names></name><name><surname>Brouwer</surname><given-names>M</given-names></name><name><surname>Donner</surname><given-names>C</given-names></name><name><surname>Liesnard</surname><given-names>C</given-names></name><name><surname>Tackoen</surname><given-names>M</given-names></name><name><surname>Van Rysselberge</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Human cytomegalovirus elicits fetal gammadelta T cell responses in utero</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>:<fpage>807</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20090348</pub-id><?supplied-pmid 20368575?><pub-id pub-id-type="pmid">20368575</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajoriya</surname><given-names>N</given-names></name><name><surname>Fergusson</surname><given-names>JR</given-names></name><name><surname>Leithead</surname><given-names>JA</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name></person-group>. <article-title>Gamma delta T-lymphocytes in hepatitis C and chronic liver disease</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<fpage>400</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2014.00400</pub-id><?supplied-pmid 25206355?><pub-id pub-id-type="pmid">25206355</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenna</surname><given-names>T</given-names></name><name><surname>Golden-Mason</surname><given-names>L</given-names></name><name><surname>Norris</surname><given-names>S</given-names></name><name><surname>Hegarty</surname><given-names>JE</given-names></name><name><surname>O&#x02019;Farrelly</surname><given-names>C</given-names></name><name><surname>Doherty</surname><given-names>DG</given-names></name></person-group>. <article-title>Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver</article-title>. <source>Clin Immunol</source> (<year>2004</year>) <volume>113</volume>:<fpage>56</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2004.05.003</pub-id><?supplied-pmid 15380530?><pub-id pub-id-type="pmid">15380530</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Functional dichotomy of Vdelta2 gammadelta T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-gamma production</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>26296</fpage><pub-id pub-id-type="doi">10.1038/srep26296</pub-id><pub-id pub-id-type="pmid">27192960</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimini</surname><given-names>E</given-names></name><name><surname>Bordoni</surname><given-names>V</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><name><surname>Visco-Comandini</surname><given-names>U</given-names></name><name><surname>Montalbano</surname><given-names>M</given-names></name><name><surname>Taibi</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Intrahepatic Vgamma9Vdelta2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication</article-title>. <source>Virus Res</source> (<year>2018</year>) <volume>243</volume>:<fpage>31</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.virusres.2017.10.008</pub-id><pub-id pub-id-type="pmid">29029951</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanayama</surname><given-names>K</given-names></name><name><surname>Morise</surname><given-names>K</given-names></name><name><surname>Nagura</surname><given-names>H</given-names></name></person-group>. <article-title>Immunohistochemical study of T cell receptor gamma delta cells in chronic liver disease</article-title>. <source>Am J Gastroenterol</source> (<year>1992</year>) <volume>87</volume>:<fpage>1018</fpage>&#x02013;<lpage>22</lpage>.<?supplied-pmid 1386494?><pub-id pub-id-type="pmid">1386494</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CT</given-names></name><name><surname>Miskovsky</surname><given-names>E</given-names></name><name><surname>Houghton</surname><given-names>M</given-names></name><name><surname>Klimpel</surname><given-names>GR</given-names></name></person-group>. <article-title>Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections</article-title>. <source>Hepatology</source> (<year>2001</year>) <volume>33</volume>:<fpage>1312</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1053/jhep.2001.24269</pub-id><?supplied-pmid 11343261?><pub-id pub-id-type="pmid">11343261</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrati</surname><given-names>C</given-names></name><name><surname>D&#x02019;Offizi</surname><given-names>G</given-names></name><name><surname>Narciso</surname><given-names>P</given-names></name><name><surname>Abrignani</surname><given-names>S</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name><name><surname>Colizzi</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons</article-title>. <source>Mol Med</source> (<year>2001</year>) <volume>7</volume>:<fpage>11</fpage>&#x02013;<lpage>9</lpage>.<?supplied-pmid 11474123?><pub-id pub-id-type="pmid">11474123</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deignan</surname><given-names>T</given-names></name><name><surname>Curry</surname><given-names>MP</given-names></name><name><surname>Doherty</surname><given-names>DG</given-names></name><name><surname>Golden-Mason</surname><given-names>L</given-names></name><name><surname>Volkov</surname><given-names>Y</given-names></name><name><surname>Norris</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection</article-title>. <source>J Hepatol</source> (<year>2002</year>) <volume>37</volume>:<fpage>101</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/S0168-8278(02)00072-7</pub-id><?supplied-pmid 12076868?><pub-id pub-id-type="pmid">12076868</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig-Pey</surname><given-names>I</given-names></name><name><surname>Bohne</surname><given-names>F</given-names></name><name><surname>Benitez</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Martinez-Llordella</surname><given-names>M</given-names></name><name><surname>Oppenheimer</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Characterization of gammadelta T cell subsets in organ transplantation</article-title>. <source>Transpl Int</source> (<year>2010</year>) <volume>23</volume>:<fpage>1045</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1111/j.1432-2277.2010.01095.x</pub-id><pub-id pub-id-type="pmid">20477999</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrati</surname><given-names>C</given-names></name><name><surname>D&#x02019;Offizi</surname><given-names>G</given-names></name><name><surname>Narciso</surname><given-names>P</given-names></name><name><surname>Selva</surname><given-names>C</given-names></name><name><surname>Pucillo</surname><given-names>LP</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Gammadelta T cell activation by chronic HIV infection may contribute to intrahepatic vdelta1 compartmentalization and hepatitis C virus disease progression independent of highly active antiretroviral therapy</article-title>. <source>AIDS Res Hum Retroviruses</source> (<year>2001</year>) <volume>17</volume>:<fpage>1357</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1089/08892220152596614</pub-id><?supplied-pmid 11602046?><pub-id pub-id-type="pmid">11602046</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrati</surname><given-names>C</given-names></name><name><surname>Alonzi</surname><given-names>T</given-names></name><name><surname>De Santis</surname><given-names>R</given-names></name><name><surname>Castilletti</surname><given-names>C</given-names></name><name><surname>Abbate</surname><given-names>I</given-names></name><name><surname>Capobianchi</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication</article-title>. <source>Int Immunol</source> (<year>2006</year>) <volume>18</volume>:<fpage>11</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxh337</pub-id><?supplied-pmid 16361319?><pub-id pub-id-type="pmid">16361319</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par</surname><given-names>G</given-names></name><name><surname>Rukavina</surname><given-names>D</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name><name><surname>Horanyi</surname><given-names>M</given-names></name><name><surname>Szekeres-Bartho</surname><given-names>J</given-names></name><name><surname>Hegedus</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection</article-title>. <source>J Hepatol</source> (<year>2002</year>) <volume>37</volume>:<fpage>514</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/S0168-8278(02)00218-0</pub-id><?supplied-pmid 12217606?><pub-id pub-id-type="pmid">12217606</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimini</surname><given-names>E</given-names></name><name><surname>Bonnafous</surname><given-names>C</given-names></name><name><surname>Bordoni</surname><given-names>V</given-names></name><name><surname>Lalle</surname><given-names>E</given-names></name><name><surname>Sicard</surname><given-names>H</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Interferon-alpha improves phosphoantigen-induced Vgamma9Vdelta2 T-cells interferon-gamma production during chronic HCV infection</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e37014</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0037014</pub-id><pub-id pub-id-type="pmid">22629350</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimini</surname><given-names>E</given-names></name><name><surname>Bonnafous</surname><given-names>C</given-names></name><name><surname>Sicard</surname><given-names>H</given-names></name><name><surname>Vlassi</surname><given-names>C</given-names></name><name><surname>D&#x02019;Offizi</surname><given-names>G</given-names></name><name><surname>Capobianchi</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>In vivo interferon-alpha/ribavirin treatment modulates Vgamma9Vdelta2 T-cell function during chronic HCV infection</article-title>. <source>J Interferon Cytokine Res</source> (<year>2013</year>) <volume>33</volume>:<fpage>136</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1089/jir.2012.0050</pub-id><pub-id pub-id-type="pmid">23308376</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedemeyer</surname><given-names>H</given-names></name></person-group>
<article-title>Towards interferon-free treatment for all HCV genotypes</article-title>. <source>Lancet</source> (<year>2015</year>) <volume>385</volume>:<fpage>2443</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(15)60605-5</pub-id><pub-id pub-id-type="pmid">25837828</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Honer Zu Siederdissen</surname><given-names>C</given-names></name><name><surname>Port</surname><given-names>K</given-names></name><name><surname>Solbach</surname><given-names>P</given-names></name><name><surname>Sollik</surname><given-names>L</given-names></name><name><surname>Kirschner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies</article-title>. <source>Aliment Pharmacol Ther</source> (<year>2015</year>) <volume>42</volume>:<fpage>889</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="doi">10.1111/apt.13343</pub-id><?supplied-pmid 26250762?><pub-id pub-id-type="pmid">26250762</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Columbo</surname><given-names>M</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Ijzermans</surname><given-names>J</given-names></name><name><surname>Paradis</surname><given-names>VL</given-names></name><name><surname>Reeves</surname><given-names>H</given-names></name><name><surname>Vilgrain</surname><given-names>VL</given-names></name><etal/></person-group>
<article-title>EASL clinical practice guidelines on the management of benign liver tumours</article-title>. <source>J Hepatol</source> (<year>2016</year>) <volume>65</volume>:<fpage>386</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1016/j.jhep.2016.04.001</pub-id><pub-id pub-id-type="pmid">27085809</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolte</surname><given-names>FJ</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>AC</given-names></name><name><surname>Webb</surname><given-names>LM</given-names></name><name><surname>Serti</surname><given-names>E</given-names></name><name><surname>Rivera</surname><given-names>E</given-names></name><name><surname>Liang</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation</article-title>. <source>Gastroenterology</source> (<year>2017</year>) <volume>153</volume>:<fpage>1392</fpage>&#x02013;<lpage>403.e1392</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2017.07.043</pub-id><?supplied-pmid 28780074?><pub-id pub-id-type="pmid">28780074</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengst</surname><given-names>J</given-names></name><name><surname>Strunz</surname><given-names>B</given-names></name><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Leeansyah</surname><given-names>E</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><etal/></person-group>
<article-title>Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy</article-title>. <source>Eur J Immunol</source> (<year>2016</year>) <volume>46</volume>:<fpage>2204</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201646447</pub-id><?supplied-pmid 27296288?><pub-id pub-id-type="pmid">27296288</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengst</surname><given-names>J</given-names></name><name><surname>Falk</surname><given-names>CS</given-names></name><name><surname>Schlaphoff</surname><given-names>V</given-names></name><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C</article-title>. <source>J Infect Dis</source> (<year>2016</year>) <volume>214</volume>:<fpage>1965</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jiw457</pub-id><?supplied-pmid 27683821?><pub-id pub-id-type="pmid">27683821</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaan</surname><given-names>M</given-names></name><name><surname>Hullegie</surname><given-names>SJ</given-names></name><name><surname>Beudeker</surname><given-names>BJ</given-names></name><name><surname>Kreefft</surname><given-names>K</given-names></name><name><surname>van Oord</surname><given-names>GW</given-names></name><name><surname>Groothuismink</surname><given-names>ZM</given-names></name><etal/></person-group>
<article-title>Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0159243</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0159243</pub-id><?supplied-pmid 27416100?><pub-id pub-id-type="pmid">27416100</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serti</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Keane</surname><given-names>M</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>AC</given-names></name><name><surname>Rivera</surname><given-names>E</given-names></name><name><surname>Liang</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha</article-title>. <source>Gut</source> (<year>2017</year>) <volume>66</volume>:<fpage>724</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1136/gutjnl-2015-310033</pub-id><pub-id pub-id-type="pmid">26733671</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>MS</given-names></name><name><surname>Willcox</surname><given-names>CR</given-names></name><name><surname>Joyce</surname><given-names>SP</given-names></name><name><surname>Ladell</surname><given-names>K</given-names></name><name><surname>Kasatskaya</surname><given-names>SA</given-names></name><name><surname>McLaren</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Clonal selection in the human Vdelta1 T cell repertoire indicates gammadelta TCR-dependent adaptive immune surveillance</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>:<fpage>14760</fpage><pub-id pub-id-type="doi">10.1038/ncomms14760</pub-id><pub-id pub-id-type="pmid">28248310</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherwood</surname><given-names>AM</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>RJ</given-names></name><name><surname>Andriesen</surname><given-names>J</given-names></name><name><surname>Haussler</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><etal/></person-group>
<article-title>Deep sequencing of the human TCRgamma and TCRbeta repertoires suggests that TCRbeta rearranges after alphabeta and gammadelta T cell commitment</article-title>. <source>Sci Transl Med</source> (<year>2011</year>) <volume>3</volume>:<fpage>90ra61</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002536</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>PL</given-names></name><name><surname>Sumaria</surname><given-names>N</given-names></name><name><surname>Holland</surname><given-names>CJ</given-names></name><name><surname>Bradford</surname><given-names>CM</given-names></name><name><surname>Izotova</surname><given-names>N</given-names></name><name><surname>Grandjean</surname><given-names>CL</given-names></name><etal/></person-group>
<article-title>Heterogeneous yet stable Vdelta2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2016</year>) <volume>113</volume>:<fpage>14378</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1611098113</pub-id><pub-id pub-id-type="pmid">27911793</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Bagaev</surname><given-names>DV</given-names></name><name><surname>Turchaninova</surname><given-names>MA</given-names></name><name><surname>Bolotin</surname><given-names>DA</given-names></name><name><surname>Britanova</surname><given-names>OV</given-names></name><name><surname>Putintseva</surname><given-names>EV</given-names></name><etal/></person-group>
<article-title>VDJtools: unifying post-analysis of T cell receptor repertoires</article-title>. <source>PLoS Comput Biol</source> (<year>2015</year>) <volume>11</volume>:<fpage>e1004503</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004503</pub-id><?supplied-pmid 26606115?><pub-id pub-id-type="pmid">26606115</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarov</surname><given-names>VI</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Zvyagin</surname><given-names>IV</given-names></name><name><surname>Bolotin</surname><given-names>DA</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>tcR: an R package for T cell receptor repertoire advanced data analysis</article-title>. <source>BMC Bioinformatics</source> (<year>2015</year>) <volume>16</volume>:<fpage>175</fpage>.<pub-id pub-id-type="doi">10.1186/s12859-015-0613-1</pub-id><?supplied-pmid 26017500?><pub-id pub-id-type="pmid">26017500</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauza</surname><given-names>CD</given-names></name><name><surname>Poonia</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cairo</surname><given-names>C</given-names></name><name><surname>Chaudhry</surname><given-names>S</given-names></name></person-group>
<article-title>&#x003b3;&#x003b4; T cells in HIV disease: past, present, and future</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>5</volume>:<fpage>687</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00687</pub-id><pub-id pub-id-type="pmid">25688241</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairallah</surname><given-names>C</given-names></name><name><surname>Dechanet-Merville</surname><given-names>J</given-names></name><name><surname>Capone</surname><given-names>M</given-names></name></person-group>
<article-title>&#x003b3;&#x003b4; T cell-mediated immunity to cytomegalovirus infection</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>8</volume>:<fpage>105</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00105</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimova</surname><given-names>T</given-names></name><name><surname>Brouwer</surname><given-names>M</given-names></name><name><surname>Gosselin</surname><given-names>F</given-names></name><name><surname>Tassignon</surname><given-names>J</given-names></name><name><surname>Leo</surname><given-names>O</given-names></name><name><surname>Donner</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Effector Vgamma9Vdelta2 T cells dominate the human fetal gammadelta T-cell repertoire</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2015</year>) <volume>112</volume>:<fpage>E556</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1412058112</pub-id><pub-id pub-id-type="pmid">25617367</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mettke</surname><given-names>F</given-names></name><name><surname>Schlevogt</surname><given-names>B</given-names></name><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Wranke</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Port</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis</article-title>. <source>Aliment Pharmacol Ther</source> (<year>2017</year>) <volume>47</volume>(<issue>4</issue>):<fpage>516</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1111/apt.14427</pub-id><pub-id pub-id-type="pmid">29205405</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serti</surname><given-names>E</given-names></name><name><surname>Chepa-Lotrea</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Keane</surname><given-names>M</given-names></name><name><surname>Fryzek</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function</article-title>. <source>Gastroenterology</source> (<year>2015</year>) <volume>149</volume>:<fpage>190</fpage>&#x02013;<lpage>200.e2</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2015.03.004</pub-id><?supplied-pmid 25754160?><pub-id pub-id-type="pmid">25754160</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaan</surname><given-names>M</given-names></name><name><surname>van Oord</surname><given-names>G</given-names></name><name><surname>Kreefft</surname><given-names>K</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>BE</given-names></name><name><surname>Janssen</surname><given-names>HL</given-names></name><etal/></person-group>
<article-title>Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment</article-title>. <source>J Infect Dis</source> (<year>2016</year>) <volume>213</volume>:<fpage>216</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jiv391</pub-id><?supplied-pmid 26223768?><pub-id pub-id-type="pmid">26223768</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burchill</surname><given-names>MA</given-names></name><name><surname>Golden-Mason</surname><given-names>L</given-names></name><name><surname>Wind-Rotolo</surname><given-names>M</given-names></name><name><surname>Rosen</surname><given-names>HR</given-names></name></person-group>. <article-title>Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals</article-title>. <source>J Viral Hepat</source> (<year>2015</year>) <volume>22</volume>:<fpage>983</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1111/jvh.12465</pub-id><?supplied-pmid 26482547?><pub-id pub-id-type="pmid">26482547</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Hennecke</surname><given-names>N</given-names></name><name><surname>Lohmann</surname><given-names>V</given-names></name><name><surname>Kayser</surname><given-names>A</given-names></name><name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name><name><surname>Kukolj</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Restoration of HCV-specific CD8+ T cell function by interferon-free therapy</article-title>. <source>J Hepatol</source> (<year>2014</year>) <volume>61</volume>:<fpage>538</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.jhep.2014.05.043</pub-id><?supplied-pmid 24905492?><pub-id pub-id-type="pmid">24905492</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langhans</surname><given-names>B</given-names></name><name><surname>Nischalke</surname><given-names>HD</given-names></name><name><surname>Kramer</surname><given-names>B</given-names></name><name><surname>Hausen</surname><given-names>A</given-names></name><name><surname>Dold</surname><given-names>L</given-names></name><name><surname>van Heteren</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Increased peripheral CD4(+) regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C</article-title>. <source>J Hepatol</source> (<year>2017</year>) <volume>66</volume>:<fpage>888</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/j.jhep.2016.12.019</pub-id><pub-id pub-id-type="pmid">28040549</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wilgenburg</surname><given-names>B</given-names></name><name><surname>Scherwitzl</surname><given-names>I</given-names></name><name><surname>Hutchinson</surname><given-names>EC</given-names></name><name><surname>Leng</surname><given-names>T</given-names></name><name><surname>Kurioka</surname><given-names>A</given-names></name><name><surname>Kulicke</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>MAIT cells are activated during human viral infections</article-title>. <source>Nat Commun</source> (<year>2016</year>) <volume>7</volume>:<fpage>11653</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms11653</pub-id><?supplied-pmid 27337592?><pub-id pub-id-type="pmid">27337592</pub-id></mixed-citation></ref></ref-list></back></article>